MultiOmyx 101: An Introduction to Multiplexing Technology
Cancer claims more than half a million lives each year in the United States alone.
Comprehensive Genomic Profiling (CGP) expands precision medicine’s utility
With the first TKI therapy Imatinib (Gleevec) targeting the fusion BCR-ABL1, approved by FDA in 2001, we have witnessed the birth of modern targeted therapy and personalized medicine.
NeoGenomics will be exhibiting at the 2022 ASCO Annual Meeting from June 4 – 6
NeoGenomics will be exhibiting at the 2022 ASCO Annual Meeting from June 4 – 6, 2022.
Join NeoGenomics for our upcoming Diagnostic Symposium on Tuesday, May 10, 9 to 10 a.m. PT.
On Saturday, March the 12th, after 28 days in China, I was finally allowed to travel to Suzhou.
My life as a volunteer prisoner ended on Friday the 4th of March. I have to admit that it has been a pretty gloomy three weeks.
Talking Cancer: Conversation with Ultramarathoner, Triathlete, Mother, Wife, Business Owner and Overachiever, Isabella de la Houssaye
To say Isabella de la Houssaye is an overachiever, would be minimizing what she is—a triathlete, a climber, a marathoner, a long-distance runner, a mother, wife and business owner, she epitomizes a